#United States #New York #AI Technology #MSK Cancer Center #Triomics

Triomics and Memorial Sloan Kettering Partnership

In an exciting development for cancer research and treatment, Triomics, a pioneer in generative AI dedicated to oncology, has announced a collaboration with the Memorial Sloan Kettering (MSK) Cancer Center. This partnership aims to incorporate the Triomics AI platform into MSK's clinical trial screening process, revolutionizing how eligible patients are matched with clinical trials.

The volume of oncology medical records has grown substantially over the years, with many clinical trial portfolios at leading medical centers becoming increasingly intricate. Traditionally, pre-screening a patient for clinical trial eligibility can consume between 30 to 45 minutes due to the meticulous scrutiny of clinician notes and lengthy PDFs. Addressing this challenge, Triomics' platform utilizes advanced AI to automatically analyze patient records, thereby identifying suitable clinical trials quickly and efficiently. This systematic approach not only enhances the screening process but also provides a detailed rationale for each match, complete with source citations, thus empowering healthcare providers to make informed decisions with increased speed and confidence.

The collaboration will commence with the deployment of the AI screening system to MSK's live clinical trials. This integration is planned in two phases, eventually extending to cover MSK’s entire portfolio of ongoing clinical trials. Moreover, the partnership intends to explore the capabilities of Triomics' platform in decentralized clinical trials conducted in MSK's affiliated satellite clinics and partnering institutions across the tri-state area.

Sarim Khan, co-founder and CEO of Triomics, expressed his enthusiasm by stating, "MSK sets the standard for translating breakthrough science into patient care. We're honored to collaborate with their team to bring production-grade AI into clinical workflows." This statement underscores the profound impact that advanced technology can have on improving patient outcomes in the complex field of oncology.

Joseph Lengfellner, Senior Director of Clinical Research Information Technology at MSK, also shared his optimistic outlook on this partnership, stating, "We look forward to working with Triomics on the rollout of this innovative technology. Real-time, evidence-linked matching transforms clinical trial screening from a bottleneck into an enabler. We expect this collaboration to enable our teams to surface opportunities that might otherwise be missed and offer trials to more patients.” The seamless integration of AI into clinical workflows only enhances the potential to connect more patients with viable trial opportunities, which is crucial for advancing cancer research and treatment options.

In addition to the deployment of the AI technology, Paul Sabbatini, the Senior Vice President for Clinical Research at MSK, will join Triomics' Customer Advisory Board. His involvement will guide the responsible scaling of the technology across Triomics’ extensive network of partner cancer centers. This collaboration reinforces the commitment of both organizations to pushing the boundaries of clinical research and patient care in oncology.

As Triomics and MSK embark on this journey together, they exemplify how innovative technology can significantly enhance efficiency and effectiveness in addressing one of humanity’s most pressing health challenges - cancer. With consortiums and partnerships like this, the future of cancer treatment promises to be brighter, bringing hope to countless patients worldwide.

Conclusion

This collaboration between Triomics and Memorial Sloan Kettering Cancer Center is a pivotal step in the integration of AI technologies in healthcare. By transforming the clinical trial screening process, they pave the way for more patient-centered care, faster treatment advancements, and ultimately, improved patient survival rates. Together, they are setting a new standard in cancer research and treatment methodologies.